Raptor Pharmaceutical Corp. (NASDAQ:RPTP) was down 2.2% on Tuesday . The company traded as low as $6.53 and last traded at $6.64, with a volume of 439,215 shares changing hands. The stock had previously closed at $6.79.

A number of equities research analysts have weighed in on RPTP shares. Wedbush reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Raptor Pharmaceutical Corp. in a report on Friday, May 6th. Zacks Investment Research raised Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a report on Thursday, August 11th. Citigroup Inc. downgraded Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and raised their target price for the company from $6.00 to $8.00 in a report on Monday, August 8th. Finally, FBR & Co reissued a “hold” rating on shares of Raptor Pharmaceutical Corp. in a report on Sunday, June 12th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Raptor Pharmaceutical Corp. has an average rating of “Hold” and an average price target of $7.21.

The company’s market capitalization is $650.88 million. The stock has a 50-day moving average of $6.10 and a 200 day moving average of $5.04.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last issued its earnings results on Thursday, August 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The business had revenue of $32.05 million for the quarter, compared to the consensus estimate of $28.52 million. The company’s revenue was up 37.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.17) EPS. On average, equities research analysts anticipate that Raptor Pharmaceutical Corp. will post ($0.90) earnings per share for the current year.

An institutional investor recently raised its position in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. raised its position in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned about 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 at the end of the most recent quarter.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.